European Journal of Pain

Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore

Retrieved on: 
Thursday, July 21, 2022
Biotechnology, Diabetes, Health, Pharmaceutical, Oncology, National, NIH, Neuropathic pain, Fast track (FDA), CEO, East End (Long Island), Partnership, CNS, Limited, Chronic pain, USD, Help End Marijuana Prohibition (HEMP) Party, Pharmacology, Migraine, Clinical trial, CIPN, ADHD, Pivotal, MD, Patient, European Journal of Pain, Depression, Chemotherapy-induced peripheral neuropathy, Drug development, IND, Pharmaceutical industry, PDPN, Greater China, Mainland China

Under the terms of the agreement, Novaremed will grant NeuroFront an exclusive option to obtain exclusive development, commercialization and manufacturing rights to NRD.E1, Novaremeds first-in-class, innovative non-opioid investigational drug candidate for the treatment of neuropathic pain.

Key Points: 
  • Under the terms of the agreement, Novaremed will grant NeuroFront an exclusive option to obtain exclusive development, commercialization and manufacturing rights to NRD.E1, Novaremeds first-in-class, innovative non-opioid investigational drug candidate for the treatment of neuropathic pain.
  • The agreement allows NeuroFront to develop and commercialize NRD.E1 as treatment of painful diabetic peripheral neuropathy (PDPN) and any other neuropathic pain indications in the Greater China territory (including Mainland China, Hong Kong, Macau, and Taiwan) and Singapore.
  • We are very delighted collaborating with NeuroFront to advance our non-opioid neuropathic pain treatment for patients suffering from PDPN and other neuropathic pain indications in China.
  • NeuroFront is very excited to partner with Novaremed to change the lives of many PDPN patients in Greater China and Singapore.

Novaremed Announces Publication of Phase 1 and Phase 2a Study Data With NRD.E1 Demonstrating the Potential of This Investigational Non-opioid Pain Treatment

Retrieved on: 
Thursday, June 23, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Diabetes, Clinical Trials, Doctor of Philosophy, FDA, CIPN, Publication, East End (Long Island), Chemotherapy-induced peripheral neuropathy, European Journal of Pain, Help End Marijuana Prohibition (HEMP) Party, PDPN, Drug development, Chronic pain, IND, Fast track (FDA), Food, Pharmacology, Patient, NIH, Pharmaceutical industry, Pain

Based on the data now published in peer-reviewed journals, we are encouraged about the potential of NRD.E1 to address the high unmet medical need for a non-opioid agent to treat chronic pain.

Key Points: 
  • Based on the data now published in peer-reviewed journals, we are encouraged about the potential of NRD.E1 to address the high unmet medical need for a non-opioid agent to treat chronic pain.
  • In three Phase 1 studies NRD.E1 was well tolerated as single dose up to 1200 mg and repeated doses of 300 mg/day for five consecutive days.
  • The Phase 2a study was a randomized, double-blind, placebo-controlled, dose-finding, proof-of-concept study in 88 patients with PDPN.
  • The study investigated NRD.E1 at 10, 40, or 150 mg/day or placebo over a 3-week treatment period.

Novaremed’s Non-opioid Lead Compound, NRD.E1, to be Tested in NIH HEAL Initiative Phase 2 Trial for the Treatment of Chronic Pain

Retrieved on: 
Tuesday, December 21, 2021
Oncology, Health, Diabetes, Clinical Trials, Pharmaceutical, Biotechnology, Doctor of Philosophy, Adult, Review, Neuropathic pain, Chronic pain, Astrophysics Strategic Mission Concept Studies, PDPN, Board, European Journal of Pain, National, Diabetes, European Journal, Sleep, IND, CIPN, Chemotherapy-induced peripheral neuropathy, Safety, Prevalence, MD, Fast track (FDA), Pharmacokinetics, Nerve injury, NIH, Cancer, Patient, US, Pharmaceutical industry, Dentistry, Pain, NRD.E1, NIH, NIH-HEAL and EPPIC-Net, peripheral neuropathy and associated neuropathic pain, Novaremed, NRD.E1, NIH, NIH-HEAL AND EPPIC-NET, PERIPHERAL NEUROPATHY AND ASSOCIATED NEUROPATHIC PAIN, NOVAREMED

After a thorough review by pain experts, Novaremed has received NIH confirmation for funding and execution of a Phase 2b study with NRD.E1 in patients with PDPN.

Key Points: 
  • After a thorough review by pain experts, Novaremed has received NIH confirmation for funding and execution of a Phase 2b study with NRD.E1 in patients with PDPN.
  • For this phase 2 investigational trial, Novaremed will provide drug supply and EPPIC-Net (Early Phase Pain Investigation Clinical Network), which is part of the NIH HEAL Initiative, will run the study in the United States.
  • The EPPIC-Net (Early Phase Pain Investigation Clinical Network) is part of the NIH HEAL Initiative and seeks to enhance the treatment of acute and chronic pain and reduce reliance on opioids by accelerating early-phase clinical trials of non-addictive treatments for pain.
  • Many of the currently available products for the treatment of chronic neuropathic pain have limited efficacy and are often not well tolerated.

AlgoTherapeutix appoints Prof Jens Ellrich Chief Medical Officer

Retrieved on: 
Monday, November 8, 2021
Biotechnology, Pharmaceutical, Health, University, EBS, European Journal of Pain, Charles V European Award, MD, Neuroscience, CEO, Doctor of Philosophy, Peripheral neuropathy, Research, Editorial, University of Erlangen–Nuremberg, Peer review, Publication, RWTH Aachen University, European Journal, Aalborg University, WISE, Pharmaceutical industry

Jens Ellrich, MD, PhD, spent 18 years in basic and clinical pain research at University hospitals in Germany and Denmark with a track record of more than 85 publications in scientific journals with peer review.

Key Points: 
  • Jens Ellrich, MD, PhD, spent 18 years in basic and clinical pain research at University hospitals in Germany and Denmark with a track record of more than 85 publications in scientific journals with peer review.
  • Since 2010, Jens has served as Chief Medical Officer for the international neuroscience start-ups Cerbomed, EBS Technologies, Precisis, Sapiens, and WISE.
  • Jens brings a wealth of hands-on experience and expertise in pain research, clinical development, and medical affairs.
  • About AlgoTherapeutix : AlgoTherapeutix is a French biotech founded in 2018 to develop innovative solutions for complex pain.